07:00 , Jul 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Perlecan Rodent studies suggest that perlecan domain V (DV) could help treat stroke. In rat and...
07:00 , May 21, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease ...
08:00 , Feb 25, 2008 |  BioCentury  |  Strategy

Offloading R&D in India

Ranbaxy Laboratories Ltd. last week became the latest Indian pharmaceutical company to demerge its drug discovery activities into a standalone subsidiary. While the company, like others that have taken a similar route, claims that the...
07:00 , Oct 3, 2005 |  BC Week In Review  |  Company News

Dr. Reddy's endocrine, cardiovascular news

RDY spun out Perlecan Pharma Private Ltd. to develop therapeutics for endocrine and cardiovascular diseases. The newco takes with it four NCEs: DRF 10945, a non-fibrate, predominantly PPAR alpha agonist that has completed Phase I...
01:59 , Sep 29, 2005 |  BC Extra  |  Company News

Dr. Reddy's spins out Perlecan

RDY spun out Perlecan to develop therapeutics for endocrine and cardiovascular diseases. The newco takes with it four NCEs: DRF 10945, a non-fibrate, predominantly PPAR alpha agonist that has completed Phase I testing for dyslipidemia;...
08:00 , Feb 14, 2005 |  BC Week In Review  |  Clinical News

RUS 3108: Started Phase I

RDY started a placebo-controlled, European Phase I trial. Dr. Reddy's Laboratories Ltd. (RDY), Hyderabad, India  Product: RUS 3108  Business: Cardiovascular  Molecular target: Perlecan  Description: Perlecan Inducer  Indication: Treat atherosclerosis  Endpoint: Safety and pharmacokinetics  Status: Started Phase I   Milestone: NA  ...